Stockscreener 앱 받기
0.7902
5.94%
-0.0498
전일 마감가:
$0.84
열려 있는:
$0.84
하루 거래량:
2.32M
Relative Volume:
0.34
시가총액:
$48.98M
수익:
-
순이익/손실:
$-22.83M
주가수익비율:
-1.0003
EPS:
-0.79
순현금흐름:
$-20.87M
1주 성능:
+12.87%
1개월 성능:
+163.37%
6개월 성능:
+4.11%
1년 성능:
-66.66%
1일 변동 폭
$0.78
$0.8499
1주일 범위
$0.681
$0.8701
52주 변동 폭
$0.2223
$2.05
Cognition Therapeutics Inc Stock (CGTX) Company Profile
명칭
Cognition Therapeutics Inc
전화
412-481-2210
주소
2403 SIDNEY STREET, PITTSBURGH
CGTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CGTX
Cognition Therapeutics Inc
|
0.7901 | 52.07M | 0 | -22.83M | -20.87M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.12 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
565.95 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.76 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
596.51 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
297.79 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2024-07-30 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-11-03 | 개시 | B. Riley Securities | Buy |
| 2021-11-03 | 개시 | Oppenheimer | Outperform |
Cognition Therapeutics Inc 주식(CGTX)의 최신 뉴스
Why is Cognition Therapeutics Inc. stock attracting strong analyst attentionMassive wealth growth - jammulinksnews.com
How volatile is Cognition Therapeutics Inc. stock compared to the marketMaximize returns with disciplined trading approaches - jammulinksnews.com
What institutional investors are buying Cognition Therapeutics Inc. stockPowerful growth strategies - jammulinksnews.com
How high can Cognition Therapeutics Inc. stock price go in 2025Profitable Yet Secure Picks - metal.it
What makes Cognition Therapeutics Inc. stock price move sharplyWeekly Big Movers - metal.it
What drives Cognition Therapeutics Inc. stock priceExceptional profit velocity - PrintWeekIndia
Cognition Therapeutics Inc. Stock Analysis and ForecastStrong return on investment - Autocar Professional
What analysts say about Cognition Therapeutics Inc. stockFree Bull & Bear Market Updates - Autocar Professional
Is Cognition Therapeutics Inc. a good long term investmentFree Predictions - jammulinksnews.com
Cognition Therapeutics Publishes Proteomic Analysis - GlobeNewswire
Cognition Therapeutics reports positive results for Alzheimer’s drug By Investing.com - Investing.com South Africa
Cognition Therapeutics Publishes Phase 2 Study Results of Zervimesine for Alzheimer's Disease in Alzheimer's & Dementia Journal - Nasdaq
Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease - The Manila Times
Cognition Therapeutics Publishes Proteomic Analysis of Zervimesine's Protective Effects on Neurons and Synapses in Alzheimer's Disease - AInvest
Breakthrough: New Alzheimer's Drug Protects Brain Cells from Death, Phase 2 Study Reveals - Stock Titan
Dementia Associated with Alzheimer’s Disease Drug - GlobeNewswire
Cognition Therapeutics shares rise 1.78% premarket after positive Phase 2 'SHIMMER' study results. - AInvest
Lewy Body Dementia Market Set to Grow Substantially Through - openPR.com
Cognition Therapeutics stock soars after DLB study results - Investing.com
Cognition Therapeutics stock soars after DLB study results By Investing.com - Investing.com Nigeria
CGTX Soars 19.72% on Promising Dementia Drug Results - AInvest
Cognition Therapeutics, Inc. Reports Promising Results for Zervimesine in Phase 2 Alzheimer’s and Dementia with Lewy Bodies Studies - Nasdaq
Cognition Therapeutics' Positive Clinical Data from - GlobeNewswire
Breakthrough DLB Treatment: Clinical Trial Reveals 86% Symptom Improvement in Dementia Patients - Stock Titan
Cognition Enhancing Drugs Market CAGR 5.6 % innovations and key - openPR.com
How Cognition Therapeutics Inc. stock performs during market volatilityMomentum Buy Alert - Newser
Cognition Therapeutics Inc (CGTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.49%
1.18%
자본화:
|
볼륨(24시간):